Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.
- Conditions
- Peripartum Cardiomyopathy
- Interventions
- Diagnostic Test: Molecular and genetic screening
- Registration Number
- NCT05878041
- Lead Sponsor
- Federico II University
- Brief Summary
Peripartum cardiomyopathy (PPCM) is a rare, severe and potentially life-threatening disorder of largely unknown etiology and pathophysiology, with unexplained geographical differences and heterogeneous presentation. Investigators hypothesize that a network-based multidisciplinary strategy integrating clinical and molecular phenotyping of PPCM patients might anticipate diagnosis, optimize treatments, and identify novel mechanisms to achieve the unmet goal of personalized medicine.
- Detailed Description
Specific aims of this study are: a) to create a multicenter pilot registry of PPCM in different areas in Italy to assess incidence and prevalence of this rare disease, associated comorbidities and risk factors. b) to deeply characterize identified PPCM patients through clinical, imaging, genetic, biochemical, and molecular phenotyping. c) to gain novel mechanistic information on PPCM by performing deep clinical and molecular phenotyping in available biobanks samples of patients with PPCM and healthy controls.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Healthy pregnant volunteers Molecular and genetic screening Healthy pregnant women Peripartum cardiomyopathy Molecular and genetic screening Diagnosis of Peripartum cardiomyopathy (PPCM) will be defined according to the ESC guidelines as: (i) the development of the disease in the last month of pregnancy or within 5 months of delivery; (i) absence of an identifiable cause of heart failure; (iii) absence of recognizable heart disease before the last month of pregnancy; (iv) left ventricle systolic dysfunction demonstrated by classical echocardiographic criteria.
- Primary Outcome Measures
Name Time Method Development of significant cardiac arrhythmias 0-6 months New onset sustained supraventricular or ventricular arrhythmias or conduction blocks during the follow-up period
Death or hospitalization due to heart failure 0-6 months Death or hospitalization due to heart failure during the follow-up period
- Secondary Outcome Measures
Name Time Method Left ventricular dysfunction 0-6 months Left ventricular % ejection fraction during the follow-up period
Trial Locations
- Locations (1)
Federico II University Hospital
🇮🇹Naples, Italy